UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000061975 |
|---|---|
| Receipt number | R000070917 |
| Scientific Title | Effects of tranexamic acid on sore throat pain associated with acute upper respiratory tract infection:a multicenter, randomized, controlled trial |
| Date of disclosure of the study information | 2026/06/19 |
| Last modified on | 2026/06/19 13:59:37 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effects of tranexamic acid on sore throat pain associated with acute upper respiratory tract infection:a multicenter, randomized, controlled trial
Acronym
Multicenter study of tranexamic acid for upper respiratory tract infection (mTURI)
Scientific Title
Effects of tranexamic acid on sore throat pain associated with acute upper respiratory tract infection:a multicenter, randomized, controlled trial
Scientific Title:Acronym
Multicenter study of tranexamic acid for upper respiratory tract infection (mTURI)
Region
| Japan |
Condition
Condition
upper respiratory tract infection
Classification by specialty
| Medicine in general |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
We investigate the efficacy of tranexamic acid on sore throat pain associated with acute URTI compared with a placebo.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Primary outcome is the difference on sore throat VAS scale between 1 day after tranexamic acid is taken.
Key secondary outcomes
The proportion of patients with sore throat score more than moderate level between 1 day after tranexamic acid is taken.
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is considered as adjustment factor in dynamic allocation.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Patients receive 1g of 50% tranexamic acid preparation three times a day.
Interventions/Control_2
Patients receive 1g placebo (lactose) three times a day.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients of upper respiratory tract infections with a complaint of sore throat, who visited a general internal medicine department office in trial hospital from July 2026 to March 2027 were registered.
Key exclusion criteria
Patients with allergy to tranexamic acid and lactose, pregnant patients or patients with possibility of pregnancy, breastfeeding patients, patients who take tranexamic acid, patients who were unable to participate the study because of dementia, visual impairment and unable to answer, or complete the study form.
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | Naoto |
| Middle name | |
| Last name | Ishimaru |
Organization
Akashi Medical Center
Division name
Department of General Internal Medicine
Zip code
6740063
Address
743-33 Yagi, Ohkubo-cho, Akashi, Hyogo 674-0063, Japan
TEL
0789361101
maru-tkb@umin.ac.jp
Public contact
Name of contact person
| 1st name | Naoto |
| Middle name | |
| Last name | Ishimaru |
Organization
Akashi Medical Center
Division name
Department of General Internal Medicine
Zip code
6740063
Address
743-33 Yagi, Ohkubo-cho, Akashi, Hyogo 674-0063, Japan
TEL
0789361101
Homepage URL
maru-tkb@umin.ac.jp
Sponsor or person
Institute
Akashi Medical Center
Institute
Department
Personal name
Funding Source
Organization
Ministry of Education, Culture, Sports, Science and Technology
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
AIJINKAI Healthcare Corporation
IRB Contact (For public release)
Organization
Institutional Review Board of Akashi Medical Center
Address
743-33 Yagi, Ohkubo-cho, Akashi, Hyogo 674-0063, Japan
Tel
0789361101
kuniyoshi.sumiko@aijinkai-group.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
利根保健生活協同組合利根中央病院（群馬県）、川崎市立多摩病院（神奈川県）
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 06 | Month | 19 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2026 | Year | 06 | Month | 19 | Day |
Date of IRB
| 2026 | Year | 06 | Month | 11 | Day |
Anticipated trial start date
| 2026 | Year | 07 | Month | 13 | Day |
Last follow-up date
| 2027 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2026 | Year | 06 | Month | 19 | Day |
Last modified on
| 2026 | Year | 06 | Month | 19 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070917
